Share on StockTwits

Consort Medical plc (LON:CSRT)‘s stock had its “buy” rating reaffirmed by equities research analysts at Canaccord Genuity in a research note issued to investors on Tuesday, AnalystRatingsNetwork.com reports. They currently have a GBX 1,044 ($17.58) price objective on the stock. Canaccord Genuity’s price target indicates a potential upside of 16.00% from the company’s current price.

Consort Medical plc (LON:CSRT) opened at 907.50 on Tuesday. Consort Medical plc has a 52-week low of GBX 733.00 and a 52-week high of GBX 1113.00. The stock has a 50-day moving average of GBX 919.2 and a 200-day moving average of GBX 945.4. The company’s market cap is £261.1 million.

Several other analysts have also recently commented on the stock. Analysts at FinnCap reiterated a “sell” rating on shares of Consort Medical plc in a research note on Tuesday. They now have a GBX 690 ($11.62) price target on the stock. Separately, analysts at Nplus1 Brewin reiterated a “hold” rating on shares of Consort Medical plc in a research note on Wednesday, March 19th. They now have a GBX 1,020 ($17.18) price target on the stock. Finally, analysts at N+1 Singer reiterated a “hold” rating on shares of Consort Medical plc in a research note on Wednesday, March 19th. They now have a GBX 1,020 ($17.18) price target on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of GBX 959.86 ($16.17).

Consort Medical plc is a healthcare company focused on medical technologies. The principal activities of the Company are the design, development and manufacture of specialty medical drug delivery devices and services to the pharmaceutical industry through its Bespak Division and disposable airway management products for critical care settings in hospitals and pre-hospital settings through its King Systems Division.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.